Therefore, any MUC1 targeted therapy must take into account not to disturb the normal MUC1, and thus a recently reported novel monoclonal antibody TAB004 (OncoTAb, Inc., Charlotte, NC, USA), which specifically targets only the tumor-associated form of MUC1 (tMUC1) may serve as the perfect delivery agent for targeting tumor MUC1 while sparing normal MUC1 [36,61,62]. The gene discussed is MUC1; the disease is neoplasm.